Rectally administered micronized progesterone for luteal phase support in hormone replacement therapy frozen embryo transfer (HRT-FET) cycle – non-inferiority randomized controlled trial

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504616-15-00

Enrollment

618

Registered

2023-06-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Ongoing pregnancy rate week 12 after HRT-FET with rectally administered progesterone, only.

Detailed description

Positive hCG rate,, Clinical pregnancy,, Pregnancy loss,, LBR,, Mean P4 levels in Group B (study group) and the relation to OPR., Urine progesterone levels in the two groups and the relation to OPR., Side effects and patient convenience regarding rectally administration of Cyclogest., Complications during the pregnancy e.g. hypertension and preeclampsia.

Interventions

DRUGCyclogest 400mg

DRUGEstrofem 2 mg Filmtabletten

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Ongoing pregnancy rate week 12 after HRT-FET with rectally administered progesterone, only.	—

Secondary

Measure	Time frame
Positive hCG rate,, Clinical pregnancy,, Pregnancy loss,, LBR,, Mean P4 levels in Group B (study group) and the relation to OPR., Urine progesterone levels in the two groups and the relation to OPR., Side effects and patient convenience regarding rectally administration of Cyclogest., Complications during the pregnancy e.g. hypertension and preeclampsia.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026